These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 33965842)

  • 1. Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy.
    Zhao C; Tang C; Li C; Ning W; Hu Z; Xin L; Zhou HB; Huang J
    Bioorg Med Chem; 2021 Jun; 40():116185. PubMed ID: 33965842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer.
    Luo G; Lin X; Ren S; Wu S; Wang X; Ma L; Xiang H
    Eur J Med Chem; 2021 Dec; 226():113870. PubMed ID: 34610548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel class of 7-Oxabicyclo[2.2.1]heptene sulfonamides with long alkyl chains displaying improved estrogen receptor α degradation activity.
    Hu Z; Li Y; Xie B; Ning W; Xiao Y; Huang Y; Zhao C; Huang J; Dong C; Zhou HB
    Eur J Med Chem; 2019 Nov; 182():111605. PubMed ID: 31437778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).
    Li Y; Zhang S; Zhang J; Hu Z; Xiao Y; Huang J; Dong C; Huang S; Zhou HB
    Eur J Med Chem; 2019 Jun; 172():48-61. PubMed ID: 30939353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.
    Tang C; Li C; Zhang S; Hu Z; Wu J; Dong C; Huang J; Zhou HB
    J Med Chem; 2015 Jun; 58(11):4550-72. PubMed ID: 25993269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Quest for Orally Available Selective Estrogen Receptor Degraders (SERDs).
    Wang L; Sharma A
    ChemMedChem; 2020 Nov; 15(22):2072-2097. PubMed ID: 32916035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
    Palermo AF; Diennet M; El Ezzy M; Williams BM; Cotnoir-White D; Mader S; Gleason JL
    Bioorg Med Chem; 2018 Aug; 26(15):4428-4440. PubMed ID: 30078609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A chimeric SERM-histone deacetylase inhibitor approach to breast cancer therapy.
    Patel HK; Siklos MI; Abdelkarim H; Mendonca EL; Vaidya A; Petukhov PA; Thatcher GR
    ChemMedChem; 2014 Mar; 9(3):602-13. PubMed ID: 23956109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new class of 1,3,5-triazine-based selective estrogen receptor degraders (SERDs): Lead optimization, molecular docking and dynamic simulation.
    Lu X; Huang A; Xiao M; Sun L; Mao J; Luo G; Xiang H
    Bioorg Chem; 2020 Apr; 97():103666. PubMed ID: 32088420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamics-Based Discovery of Novel, Potent Benzoic Acid Derivatives as Orally Bioavailable Selective Estrogen Receptor Degraders for ERα+ Breast Cancer.
    Zhang X; Wang Y; Li X; Wu J; Zhao L; Li W; Liu J
    J Med Chem; 2021 Jun; 64(11):7575-7595. PubMed ID: 34056898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and structure-activity relationships of novel hybrid ferrocenyl compounds based on a bicyclic core skeleton for breast cancer therapy.
    Li C; Tang C; Hu Z; Zhao C; Li C; Zhang S; Dong C; Zhou HB; Huang J
    Bioorg Med Chem; 2016 Jul; 24(13):3062-3074. PubMed ID: 27240467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and anticancer activity of novel valproic acid conjugates with improved histone deacetylase (HDAC) inhibitory activity.
    Ibrahim TS; Sheha TA; Abo-Dya NE; AlAwadh MA; Alhakamy NA; Abdel-Samii ZK; Panda SS; Abuo-Rahma GEA; Mohamed MFA
    Bioorg Chem; 2020 Jun; 99():103797. PubMed ID: 32247939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A potentiated cooperation of carbonic anhydrase IX and histone deacetylase inhibitors against cancer.
    Ruzzolini J; Laurenzana A; Andreucci E; Peppicelli S; Bianchini F; Carta F; Supuran CT; Romanelli MN; Nediani C; Calorini L
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):391-397. PubMed ID: 31865754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural optimization of tetrahydroisoquinoline-hydroxamate hybrids as potent dual ERα degraders and HDAC inhibitors.
    Xiong S; Wang X; Zhu M; Song K; Li Y; Yang J; Liu X; Liu M; Dong H; Chen M; Chen D; Xiang H; Luo G
    Bioorg Chem; 2023 May; 134():106459. PubMed ID: 36924653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor α (ERα) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer.
    He M; Ning W; Hu Z; Huang J; Dong C; Zhou HB
    Eur J Med Chem; 2020 Jun; 195():112281. PubMed ID: 32283297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationships of 2, 4-disubstituted pyrimidines as dual ERα/VEGFR-2 ligands with anti-breast cancer activity.
    Luo G; Tang Z; Lao K; Li X; You Q; Xiang H
    Eur J Med Chem; 2018 Apr; 150():783-795. PubMed ID: 29587221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel selective estrogen receptor degrader induces cell cycle arrest in breast cancer via ERα degradation and the autophagy-lysosome pathway.
    Zhou J; Shen R; Liu J; Deng X; Xin L; Zhou HB; Huang J
    Bioorg Med Chem; 2023 Mar; 82():117235. PubMed ID: 36905762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-guided identification of novel dual-targeting estrogen receptor α degraders with aromatase inhibitory activity for the treatment of endocrine-resistant breast cancer.
    Xin L; Min J; Hu H; Li Y; Du C; Xie B; Cheng Y; Deng X; Deng X; Shen K; Huang J; Chen CC; Guo RT; Dong C; Zhou HB
    Eur J Med Chem; 2023 May; 253():115328. PubMed ID: 37037140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel 2H-chromene-3-carbonyl derivatives as selective estrogen receptor degraders (SERDs): Design, synthesis and biological evaluation.
    Lu X; Teng Y; Lin X; Xiao M; Liu C; Chi X; Zhang Y; Luo G; Xiang H
    Bioorg Chem; 2021 Apr; 109():104714. PubMed ID: 33618254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of marine sesterterpene analogues as novel estrogen receptor α degraders for breast cancer treatment.
    Liang JJ; Yu WL; Yang L; Xie BH; Qin KM; Yin YP; Yan JJ; Gong S; Liu TY; Zhou HB; Hong K
    Eur J Med Chem; 2022 Feb; 229():114081. PubMed ID: 34992039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.